| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus | 21 | 2021 | 465 | 3.870 |
Why?
|
| Hawaii | 63 | 2024 | 1878 | 2.840 |
Why?
|
| Hospitalization | 17 | 2021 | 370 | 2.560 |
Why?
|
| Medicare | 8 | 2022 | 188 | 2.500 |
Why?
|
| Heart Failure | 7 | 2016 | 230 | 1.700 |
Why?
|
| Health Status Disparities | 9 | 2020 | 583 | 1.670 |
Why?
|
| Aged | 54 | 2022 | 6448 | 1.630 |
Why?
|
| Middle Aged | 60 | 2020 | 9642 | 1.370 |
Why?
|
| Humans | 107 | 2024 | 34853 | 1.370 |
Why?
|
| Heart Diseases | 6 | 2021 | 99 | 1.320 |
Why?
|
| Patient Compliance | 9 | 2008 | 202 | 1.300 |
Why?
|
| Medication Adherence | 6 | 2017 | 165 | 1.230 |
Why?
|
| Male | 68 | 2023 | 18870 | 1.100 |
Why?
|
| Female | 70 | 2023 | 19873 | 1.090 |
Why?
|
| Cardiovascular Diseases | 7 | 2020 | 628 | 1.070 |
Why?
|
| Managed Care Programs | 7 | 2019 | 35 | 0.990 |
Why?
|
| Health Services Accessibility | 6 | 2022 | 531 | 0.990 |
Why?
|
| Physician-Patient Relations | 6 | 2020 | 118 | 0.980 |
Why?
|
| Hypoglycemic Agents | 5 | 2017 | 152 | 0.910 |
Why?
|
| Patient Readmission | 4 | 2019 | 74 | 0.900 |
Why?
|
| Quality of Health Care | 7 | 2021 | 136 | 0.900 |
Why?
|
| United States | 21 | 2023 | 3894 | 0.900 |
Why?
|
| Aged, 80 and over | 23 | 2020 | 2333 | 0.890 |
Why?
|
| Health Literacy | 2 | 2021 | 100 | 0.860 |
Why?
|
| Seasonal Affective Disorder | 1 | 2021 | 1 | 0.850 |
Why?
|
| Adult | 39 | 2021 | 11034 | 0.850 |
Why?
|
| Healthcare Disparities | 4 | 2016 | 446 | 0.840 |
Why?
|
| Biomedical Research | 2 | 2023 | 371 | 0.830 |
Why?
|
| Health Status | 9 | 2018 | 356 | 0.750 |
Why?
|
| Parkinson Disease | 1 | 2021 | 167 | 0.740 |
Why?
|
| Office Visits | 2 | 2018 | 22 | 0.740 |
Why?
|
| Sunlight | 1 | 2020 | 46 | 0.720 |
Why?
|
| Retrospective Studies | 23 | 2020 | 1961 | 0.720 |
Why?
|
| Prescription Drugs | 2 | 2016 | 31 | 0.720 |
Why?
|
| Antihypertensive Agents | 4 | 2014 | 284 | 0.710 |
Why?
|
| Drug Prescriptions | 6 | 2016 | 42 | 0.700 |
Why?
|
| Emergency Service, Hospital | 6 | 2021 | 188 | 0.680 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 186 | 0.650 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 151 | 0.640 |
Why?
|
| Respiratory Tract Diseases | 1 | 2017 | 25 | 0.620 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 63 | 0.620 |
Why?
|
| Disabled Persons | 1 | 2018 | 60 | 0.610 |
Why?
|
| Drug Costs | 1 | 2017 | 28 | 0.610 |
Why?
|
| Health Expenditures | 1 | 2017 | 30 | 0.600 |
Why?
|
| Chronic Disease | 6 | 2023 | 469 | 0.600 |
Why?
|
| Social Class | 2 | 2018 | 228 | 0.590 |
Why?
|
| Cause of Death | 1 | 2017 | 154 | 0.590 |
Why?
|
| Health Education | 1 | 2020 | 304 | 0.590 |
Why?
|
| Hypertension | 5 | 2017 | 770 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 77 | 0.570 |
Why?
|
| Caregivers | 1 | 2018 | 167 | 0.560 |
Why?
|
| Patient Satisfaction | 4 | 2001 | 141 | 0.540 |
Why?
|
| Comorbidity | 6 | 2020 | 606 | 0.520 |
Why?
|
| Universities | 3 | 2021 | 363 | 0.510 |
Why?
|
| Smoking | 3 | 2016 | 903 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2020 | 790 | 0.500 |
Why?
|
| Young Adult | 13 | 2021 | 4012 | 0.490 |
Why?
|
| Socioeconomic Factors | 7 | 2020 | 1003 | 0.490 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 143 | 0.490 |
Why?
|
| Disease Progression | 1 | 2016 | 580 | 0.490 |
Why?
|
| Hospital Mortality | 2 | 2015 | 183 | 0.480 |
Why?
|
| Physicians | 3 | 2020 | 148 | 0.480 |
Why?
|
| Primary Health Care | 6 | 2019 | 283 | 0.450 |
Why?
|
| Insurance, Health, Reimbursement | 3 | 2015 | 20 | 0.450 |
Why?
|
| Inpatients | 3 | 2016 | 72 | 0.450 |
Why?
|
| Age Factors | 10 | 2016 | 1007 | 0.450 |
Why?
|
| Adolescent | 18 | 2020 | 5035 | 0.440 |
Why?
|
| Neoplasms | 2 | 2023 | 1033 | 0.430 |
Why?
|
| Income | 3 | 2018 | 135 | 0.370 |
Why?
|
| Pharmaceutical Preparations | 2 | 2014 | 74 | 0.370 |
Why?
|
| Reimbursement, Incentive | 3 | 2011 | 11 | 0.370 |
Why?
|
| Logistic Models | 7 | 2018 | 894 | 0.360 |
Why?
|
| Cost Sharing | 2 | 2006 | 4 | 0.360 |
Why?
|
| Ambulatory Care | 2 | 2020 | 76 | 0.360 |
Why?
|
| Educational Status | 6 | 2018 | 295 | 0.360 |
Why?
|
| Diabetes Complications | 2 | 2015 | 91 | 0.360 |
Why?
|
| Community Networks | 2 | 2020 | 98 | 0.350 |
Why?
|
| Health Care Surveys | 8 | 2007 | 136 | 0.330 |
Why?
|
| Mental Disorders | 2 | 2016 | 285 | 0.330 |
Why?
|
| Qualitative Research | 3 | 2020 | 393 | 0.320 |
Why?
|
| Preferred Provider Organizations | 2 | 2007 | 2 | 0.310 |
Why?
|
| Health Care Costs | 3 | 2012 | 69 | 0.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2015 | 64 | 0.310 |
Why?
|
| Continuity of Patient Care | 4 | 2020 | 90 | 0.300 |
Why?
|
| Health Behavior | 2 | 2004 | 491 | 0.300 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2008 | 8 | 0.300 |
Why?
|
| Costs and Cost Analysis | 3 | 2015 | 54 | 0.300 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 570 | 0.290 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 254 | 0.290 |
Why?
|
| Blood Glucose | 2 | 2022 | 333 | 0.280 |
Why?
|
| Cross-Sectional Studies | 7 | 2017 | 2561 | 0.280 |
Why?
|
| Legislation, Drug | 1 | 2015 | 5 | 0.280 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 57 | 0.270 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2015 | 6 | 0.270 |
Why?
|
| Risk Adjustment | 1 | 2015 | 17 | 0.270 |
Why?
|
| Prevalence | 6 | 2017 | 1425 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 233 | 0.270 |
Why?
|
| Myocardial Infarction | 2 | 2015 | 221 | 0.270 |
Why?
|
| Air Ambulances | 1 | 2015 | 5 | 0.260 |
Why?
|
| Ophthalmology | 1 | 2015 | 28 | 0.260 |
Why?
|
| Patient Transfer | 1 | 2015 | 22 | 0.260 |
Why?
|
| Neurosurgical Procedures | 1 | 2015 | 25 | 0.260 |
Why?
|
| Odds Ratio | 5 | 2014 | 517 | 0.250 |
Why?
|
| Insurance Claim Review | 3 | 2020 | 24 | 0.250 |
Why?
|
| Length of Stay | 1 | 2015 | 184 | 0.250 |
Why?
|
| Obesity | 2 | 2010 | 965 | 0.250 |
Why?
|
| Law Enforcement | 1 | 2014 | 13 | 0.240 |
Why?
|
| Drug and Narcotic Control | 1 | 2014 | 10 | 0.240 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 12 | 0.240 |
Why?
|
| Drug Monitoring | 1 | 2014 | 17 | 0.240 |
Why?
|
| Seasons | 2 | 2021 | 112 | 0.240 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2023 | 9 | 0.240 |
Why?
|
| Insulin | 3 | 2017 | 224 | 0.240 |
Why?
|
| Mental Health | 4 | 2017 | 270 | 0.240 |
Why?
|
| Ethics, Research | 1 | 2024 | 17 | 0.240 |
Why?
|
| Health | 1 | 2023 | 28 | 0.230 |
Why?
|
| Cerebral Hemorrhage | 1 | 2015 | 103 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 1 | 2003 | 30 | 0.230 |
Why?
|
| Health Surveys | 3 | 2017 | 358 | 0.230 |
Why?
|
| Medicare Part B | 1 | 2003 | 13 | 0.230 |
Why?
|
| Capacity Building | 1 | 2024 | 78 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 5 | 2017 | 142 | 0.230 |
Why?
|
| Patient-Centered Care | 2 | 2021 | 51 | 0.230 |
Why?
|
| Databases, Factual | 1 | 2023 | 288 | 0.220 |
Why?
|
| Influenza Vaccines | 2 | 2009 | 50 | 0.210 |
Why?
|
| Asian Americans | 1 | 2001 | 2 | 0.210 |
Why?
|
| Language | 2 | 2023 | 143 | 0.210 |
Why?
|
| Prescriptions | 1 | 2021 | 17 | 0.210 |
Why?
|
| Electronic Health Records | 2 | 2019 | 65 | 0.210 |
Why?
|
| Acupuncture Therapy | 1 | 2001 | 13 | 0.210 |
Why?
|
| Risk Factors | 9 | 2016 | 3414 | 0.210 |
Why?
|
| Attitude to Health | 2 | 2001 | 311 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 3 | 2012 | 40 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2017 | 82 | 0.200 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 55 | 0.200 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 2 | 2009 | 6 | 0.200 |
Why?
|
| Poverty | 1 | 2023 | 316 | 0.190 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 207 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2016 | 429 | 0.190 |
Why?
|
| Emergency Medical Services | 1 | 2010 | 55 | 0.190 |
Why?
|
| Suntan | 1 | 2020 | 5 | 0.190 |
Why?
|
| Sunscreening Agents | 1 | 2020 | 9 | 0.190 |
Why?
|
| Sex Factors | 3 | 2016 | 859 | 0.180 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 22 | 0.180 |
Why?
|
| Quality of Life | 2 | 2000 | 459 | 0.180 |
Why?
|
| Awareness | 1 | 2020 | 59 | 0.180 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 13 | 0.180 |
Why?
|
| Behavioral Medicine | 1 | 2019 | 10 | 0.180 |
Why?
|
| Accidental Falls | 1 | 2019 | 26 | 0.180 |
Why?
|
| Pharmacists | 1 | 2020 | 53 | 0.180 |
Why?
|
| Pharmacy | 1 | 2020 | 26 | 0.170 |
Why?
|
| Cooperative Behavior | 2 | 2019 | 205 | 0.170 |
Why?
|
| Communication Barriers | 1 | 1999 | 53 | 0.170 |
Why?
|
| Mass Screening | 3 | 2007 | 427 | 0.170 |
Why?
|
| Preventive Medicine | 1 | 2018 | 15 | 0.170 |
Why?
|
| Activities of Daily Living | 2 | 2018 | 104 | 0.160 |
Why?
|
| Writing | 1 | 2018 | 33 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2018 | 11 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2018 | 12 | 0.160 |
Why?
|
| Awards and Prizes | 1 | 2018 | 27 | 0.160 |
Why?
|
| Coronary Artery Disease | 2 | 2012 | 147 | 0.160 |
Why?
|
| Influenza, Human | 1 | 2009 | 79 | 0.160 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 132 | 0.160 |
Why?
|
| Independent Living | 1 | 2018 | 31 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 187 | 0.160 |
Why?
|
| Vision Disorders | 1 | 2018 | 59 | 0.150 |
Why?
|
| Lovastatin | 1 | 2017 | 10 | 0.150 |
Why?
|
| Asthma | 1 | 2021 | 363 | 0.150 |
Why?
|
| Simvastatin | 1 | 2017 | 28 | 0.150 |
Why?
|
| Students | 1 | 2021 | 452 | 0.150 |
Why?
|
| Family Practice | 1 | 1997 | 43 | 0.150 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 9 | 0.150 |
Why?
|
| Aging | 1 | 2011 | 639 | 0.150 |
Why?
|
| Depressive Disorder, Major | 1 | 2008 | 102 | 0.150 |
Why?
|
| Critical Pathways | 1 | 2016 | 15 | 0.150 |
Why?
|
| Bacteremia | 1 | 2016 | 31 | 0.140 |
Why?
|
| Housing | 1 | 2017 | 54 | 0.140 |
Why?
|
| Asia | 1 | 2016 | 74 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 592 | 0.140 |
Why?
|
| Cross Infection | 1 | 2016 | 38 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 415 | 0.140 |
Why?
|
| Minority Groups | 1 | 2021 | 537 | 0.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 58 | 0.140 |
Why?
|
| Reminder Systems | 2 | 2014 | 12 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2016 | 64 | 0.130 |
Why?
|
| Risk-Taking | 2 | 1998 | 435 | 0.130 |
Why?
|
| Public Health | 1 | 2019 | 348 | 0.130 |
Why?
|
| Health Promotion | 1 | 2010 | 588 | 0.130 |
Why?
|
| Massachusetts | 5 | 2001 | 29 | 0.130 |
Why?
|
| Brain Ischemia | 1 | 2016 | 179 | 0.120 |
Why?
|
| Micronesia | 1 | 2014 | 87 | 0.120 |
Why?
|
| Anticholesteremic Agents | 1 | 2014 | 23 | 0.120 |
Why?
|
| Health Status Indicators | 2 | 2006 | 73 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 355 | 0.120 |
Why?
|
| Stroke | 1 | 2016 | 274 | 0.110 |
Why?
|
| Health Services Research | 4 | 2015 | 133 | 0.110 |
Why?
|
| Follow-Up Studies | 6 | 2012 | 964 | 0.110 |
Why?
|
| Stents | 2 | 2003 | 59 | 0.110 |
Why?
|
| Medicaid | 2 | 2015 | 102 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2011 | 1349 | 0.110 |
Why?
|
| Coronary Artery Bypass | 2 | 2003 | 43 | 0.110 |
Why?
|
| Myocardial Revascularization | 2 | 2001 | 5 | 0.100 |
Why?
|
| Child | 6 | 2021 | 2875 | 0.100 |
Why?
|
| Longitudinal Studies | 4 | 2011 | 841 | 0.100 |
Why?
|
| Philippines | 2 | 2014 | 72 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2007 | 92 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2017 | 356 | 0.100 |
Why?
|
| Community Health Services | 2 | 2019 | 175 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2003 | 113 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2011 | 727 | 0.090 |
Why?
|
| Fungemia | 1 | 2008 | 3 | 0.090 |
Why?
|
| Program Evaluation | 2 | 2010 | 316 | 0.080 |
Why?
|
| Insurance Coverage | 2 | 2012 | 99 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 50 | 0.080 |
Why?
|
| Treatment Refusal | 2 | 2005 | 20 | 0.080 |
Why?
|
| Candida | 1 | 2008 | 32 | 0.080 |
Why?
|
| Electric Countershock | 2 | 1999 | 12 | 0.080 |
Why?
|
| Echocardiography, Transesophageal | 2 | 1999 | 19 | 0.080 |
Why?
|
| Physician Incentive Plans | 1 | 2007 | 2 | 0.080 |
Why?
|
| Brazil | 2 | 2023 | 66 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 54 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2009 | 775 | 0.080 |
Why?
|
| Candidiasis | 1 | 2008 | 85 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2007 | 44 | 0.080 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 7 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 2007 | 100 | 0.070 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 26 | 0.070 |
Why?
|
| Organizational Policy | 1 | 2006 | 20 | 0.070 |
Why?
|
| Atrial Fibrillation | 2 | 1999 | 105 | 0.070 |
Why?
|
| Disease Management | 1 | 2007 | 61 | 0.070 |
Why?
|
| Prepaid Health Plans | 1 | 2006 | 1 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 47 | 0.070 |
Why?
|
| Mammography | 1 | 2007 | 176 | 0.070 |
Why?
|
| Minority Health | 1 | 2016 | 81 | 0.070 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2005 | 2 | 0.070 |
Why?
|
| Pneumococcal Vaccines | 1 | 2005 | 13 | 0.070 |
Why?
|
| Immunization Programs | 1 | 2005 | 22 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 18 | 0.070 |
Why?
|
| Taxes | 1 | 2015 | 13 | 0.070 |
Why?
|
| Infant | 3 | 2010 | 1014 | 0.070 |
Why?
|
| Politics | 1 | 2015 | 35 | 0.070 |
Why?
|
| Health Maintenance Organizations | 2 | 2001 | 12 | 0.060 |
Why?
|
| Pediatrics | 1 | 2005 | 66 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2010 | 1318 | 0.060 |
Why?
|
| Algorithms | 2 | 2012 | 435 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2014 | 65 | 0.060 |
Why?
|
| Directly Observed Therapy | 1 | 2014 | 2 | 0.060 |
Why?
|
| Formularies as Topic | 1 | 2003 | 3 | 0.060 |
Why?
|
| Social Responsibility | 1 | 2003 | 12 | 0.060 |
Why?
|
| Drug Industry | 1 | 2003 | 13 | 0.060 |
Why?
|
| Community Pharmacy Services | 1 | 2014 | 24 | 0.060 |
Why?
|
| Drugs, Generic | 1 | 2003 | 4 | 0.060 |
Why?
|
| Therapies, Investigational | 1 | 2003 | 2 | 0.060 |
Why?
|
| Hospital Charges | 1 | 2003 | 13 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2003 | 22 | 0.060 |
Why?
|
| Sample Size | 1 | 2023 | 28 | 0.060 |
Why?
|
| Peer Group | 1 | 2014 | 138 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2003 | 48 | 0.060 |
Why?
|
| Hospital Bed Capacity | 1 | 2012 | 4 | 0.050 |
Why?
|
| Genomics | 1 | 2023 | 201 | 0.050 |
Why?
|
| Risk | 2 | 2009 | 256 | 0.050 |
Why?
|
| Medicare Part C | 1 | 2001 | 12 | 0.050 |
Why?
|
| Physical Examination | 1 | 2001 | 40 | 0.050 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 35 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2000 | 555 | 0.050 |
Why?
|
| Pregnancy | 1 | 2016 | 1503 | 0.050 |
Why?
|
| Demography | 1 | 2001 | 167 | 0.050 |
Why?
|
| Time Factors | 3 | 2008 | 1681 | 0.050 |
Why?
|
| Health Priorities | 1 | 2021 | 18 | 0.050 |
Why?
|
| Maryland | 1 | 2021 | 53 | 0.050 |
Why?
|
| Resource Allocation | 1 | 2021 | 11 | 0.050 |
Why?
|
| Endocarditis, Bacterial | 1 | 2000 | 4 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2000 | 7 | 0.050 |
Why?
|
| Health Services | 1 | 2010 | 53 | 0.050 |
Why?
|
| Leadership | 1 | 2021 | 63 | 0.050 |
Why?
|
| Phylogeny | 1 | 2023 | 612 | 0.050 |
Why?
|
| Substance-Related Disorders | 1 | 2007 | 685 | 0.050 |
Why?
|
| Communication | 1 | 2001 | 170 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 42 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2004 | 418 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2009 | 1422 | 0.050 |
Why?
|
| Education, Continuing | 1 | 2010 | 17 | 0.050 |
Why?
|
| Research Personnel | 1 | 2021 | 133 | 0.050 |
Why?
|
| Vaccination | 1 | 2001 | 259 | 0.050 |
Why?
|
| Linear Models | 1 | 2000 | 253 | 0.050 |
Why?
|
| Decision Trees | 1 | 1999 | 18 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 1426 | 0.040 |
Why?
|
| Myocardial Ischemia | 1 | 2000 | 72 | 0.040 |
Why?
|
| Exercise | 1 | 2004 | 524 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2008 | 151 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 423 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 301 | 0.040 |
Why?
|
| Boston | 1 | 1997 | 20 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 51 | 0.040 |
Why?
|
| Life Style | 1 | 2009 | 288 | 0.040 |
Why?
|
| Water Supply | 1 | 2017 | 54 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 1997 | 48 | 0.040 |
Why?
|
| Physicians, Women | 1 | 1996 | 4 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1996 | 44 | 0.040 |
Why?
|
| Incidence | 1 | 2009 | 882 | 0.040 |
Why?
|
| Physician's Role | 1 | 1996 | 34 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2019 | 292 | 0.030 |
Why?
|
| Pacific States | 1 | 2015 | 4 | 0.030 |
Why?
|
| Gender Identity | 1 | 1996 | 93 | 0.030 |
Why?
|
| China | 1 | 2014 | 178 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2008 | 871 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 296 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2007 | 322 | 0.030 |
Why?
|
| Population Groups | 1 | 2013 | 56 | 0.030 |
Why?
|
| Morbidity | 1 | 2012 | 94 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2015 | 1353 | 0.020 |
Why?
|
| Diet | 1 | 2017 | 747 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 222 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2008 | 24 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 2 | 1999 | 51 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 29 | 0.020 |
Why?
|
| Echocardiography | 2 | 2000 | 144 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 37 | 0.020 |
Why?
|
| Professional Competence | 1 | 2007 | 34 | 0.020 |
Why?
|
| Thrombosis | 2 | 1999 | 61 | 0.020 |
Why?
|
| Anticoagulants | 2 | 1999 | 97 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2007 | 37 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2006 | 35 | 0.020 |
Why?
|
| Geography | 1 | 2006 | 86 | 0.020 |
Why?
|
| Rural Health Services | 1 | 2006 | 39 | 0.020 |
Why?
|
| Social Justice | 1 | 2006 | 53 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 36 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2006 | 171 | 0.020 |
Why?
|
| Age Distribution | 1 | 2005 | 223 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 212 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2005 | 120 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2003 | 28 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 248 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 154 | 0.010 |
Why?
|
| Cost Savings | 1 | 2001 | 14 | 0.010 |
Why?
|
| Fee-for-Service Plans | 1 | 2001 | 16 | 0.010 |
Why?
|
| Acute Disease | 1 | 2001 | 141 | 0.010 |
Why?
|
| Group Practice, Prepaid | 1 | 2000 | 2 | 0.010 |
Why?
|
| Government Agencies | 1 | 2000 | 9 | 0.010 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2000 | 3 | 0.010 |
Why?
|
| State Government | 1 | 2000 | 11 | 0.010 |
Why?
|
| Models, Organizational | 1 | 2000 | 33 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 111 | 0.010 |
Why?
|
| Probability | 1 | 1999 | 75 | 0.010 |
Why?
|
| Survival Rate | 1 | 1998 | 310 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1997 | 46 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1997 | 37 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1998 | 231 | 0.010 |
Why?
|
| Research Design | 1 | 1998 | 292 | 0.010 |
Why?
|
| Warfarin | 1 | 1997 | 59 | 0.010 |
Why?
|
| Menopause | 1 | 1996 | 54 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 901 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1996 | 1056 | 0.010 |
Why?
|